Clinical Trials Directory

A Phase I Study of Rindopepimut After Conventional Radiation in Children With Diffuse Intrinsic Pontine Gliomas

This is a research study of patients with diffuse intrinsic pontine gliomas. We hope to learn about the safety and efficacy of treating pediatric diffuse intrinsic pontine glioma patients with the EGFRvIII peptide vaccine after conventional radiation.

Stanford is not currently accepting new patients for this trial. You may want to check to see if other locations are recruiting.



  • biological : Rindopepimut

Phase: Phase 1


Ages Eligible For Study:

3 Years - 18 Years

External Links

Explore related trials

Contact information

Primary Contact:

Christina Huang 650-723-0574

Stanford University School of Medicine 300 Pasteur Drive Stanford, CA 94305

Stanford Medicine Resources:

Footer Links: